Fisher & Paykel Healthcare: Market Too Optimistic on Pace of Hospital Adoption
Fisher & Paykel Healthcare stock has returned about 20% year to date, well ahead of the flat Morningstar Australia Healthcare Index.
Fisher & Paykel Healthcare Corp Ltd FPH
Bulls Say, Bears Say
Bulls
The long-term growth opportunity for respiratory support devices is sizable, as developing markets are still significantly underpenetrated.
Bears
Changing clinical practices to adopt NHF therapy requires more widespread clinical evidence, and even so, it is a gradual marketing process that often takes years and is hospital-specific.
Trading Information
- Previous Close Price
- NZ$48.80
- Day Range
- NZ$47.51–48.99
- 52-Week Range
- NZ$32.16–49.22
- Bid/Ask
- NZ$48.04 / NZ$48.80
- Shares Outstanding
- 588.27M
- Market Cap
- NZ$28.65B
- Volume/Avg
- 629,465 / 429,922
Key Statistics
- Price/Earnings (Normalized)
- 60.93
- Price/Sales
- 12.46
- Dividend Yield (Trailing)
- 1.07%
- Dividend Yield (Forward)
- 1.07%
- Dividend Payment Schedule
- Jul, Dec
- Total Yield
- 1.07%
Company Profile
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Large Growth
- Total Number of Employees
- 7,375
- Website
- https://www.fphcare.com
Competitors
Valuation
|
Metric
|
FPH
|
CTEC
|
COLO B
|
|---|---|---|---|
Price/Earnings (Normalized) | 60.93 | 23.76 | 35.10 |
Price/Book Value | 13.52 | 4.18 | 7.69 |
Price/Sales | 12.46 | 2.47 | 3.61 |
Price/Cash Flow | 43.38 | 13.35 | 13.12 |
Price/Earnings
FPH
CTEC
COLO B
Financial Strength
|
Metric
|
FPH
|
CTEC
|
COLO B
|
|---|---|---|---|
Quick Ratio | 1.59 | 1.06 | 0.88 |
Current Ratio | 2.31 | 1.93 | 1.56 |
Interest Coverage | 61.51 | 3.34 | 6.65 |
Quick Ratio
FPH
CTEC
COLO B
Profitability
|
Metric
|
FPH
|
CTEC
|
COLO B
|
|---|---|---|---|
Return on Assets (Normalized) | 17.34% | 9.54% | 11.86% |
Return on Equity (Normalized) | 23.25% | 22.72% | 38.99% |
Return on Invested Capital (Normalized) | 21.70% | 13.15% | 15.76% |
Return on Assets
FPH
CTEC
COLO B
Medical Instruments & Supplies Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc
ISRG
| LOCK|xgNZ#<s! | LOCK|jP | $149B | |||
| Becton Dickinson & Co
BDX
| LOCK|t< | LOCK|@BN< | $51B | |||
| ResMed Inc
RMD
| LOCK|$c>Q@^$ | LOCK|<fc># | $33B | |||
| Medline Inc Ordinary Shares - Class A
MDLN
| LOCK|V#r@&xV | LOCK|Knz> | $31B | |||
| Alcon Inc
ALC
| LOCK|%!@r&D | LOCK|%hv$S | $30B | |||
| West Pharmaceutical Services Inc
WST
| LOCK|D&@w&fw | LOCK|g?! | $26B | |||
| Solventum Corp
SOLV
| LOCK|wTgRc# | LOCK|Jl | $15B | |||
| Baxter International Inc
BAX
| LOCK|%%g | LOCK|X$h<Q | $13B | |||
| Repligen Corp
RGEN
| LOCK|>>Qm>wy# | LOCK|%r>@ | $11B | |||
| The Cooper Companies Inc
COO
| LOCK|&s@B^% | LOCK|!^%Bm | $10B |
United States